Data from Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding

Abstract

<div>Abstract<p><b>Purpose:</b> Colorectal cancer is routinely treated with a 5-fluorouracil (5-FU)–based chemotherapy. 5-FU incorporates into DNA, and the base excision repair (BER) pathway specifically recognizes such damage. We investigated the association of single-nucleotide polymorphisms (SNP) in the 3′-untranslated regions (UTR) of BER genes, and potentially affecting the microRNA (miRNA) binding, on the risk of colorectal cancer, its progression, and prognosis. SNPs in miRNA-binding sites may modulate the posttranscriptional regulation of gene expression operated by miRNAs and explain interindividual variability in BER capacity and response to 5-FU.</p><p><b>Experimental Design:</b> We tested 12 SNPs in the 3′-UTRs of five BER genes for colorectal cancer susceptibility in a case–control study (1,098 cases and 1,459 healthy controls). Subsequently, we analyzed the role of these SNPs on clinical outcomes of patients (866 in the Training set and 232 in the Replication set).</p><p><b>Results:</b> SNPs in the <i>SMUG1</i> and <i>NEIL2</i> genes were associated with overall survival. In particular, <i>SMUG1</i> rs2233921 TT carriers showed increased survival compared with those with GT/GG genotypes [HR, 0.54; 95% confidence interval (CI), 0.36–0.81; <i>P</i> = 0.003] in the Training set and after pooling results from the Replication set. The association was more significant following stratification for 5-FU–based chemotherapy (<i>P</i> = 5.6 × 10<sup>−5</sup>). A reduced expression of the reporter gene for the T allele of rs2233921 was observed when compared with the common G allele by <i>in vitro</i> assay. None of the genotyped BER polymorphisms were associated with colorectal cancer risk.</p><p><b>Conclusions:</b> We provide the first evidence that variations in miRNA-binding sites in BER genes 3′-UTR may modulate colorectal cancer prognosis and therapy response. <i>Clin Cancer Res; 19(21); 6044–56. ©2013 AACR</i>.</p></div>